Trethera News

Gloved hand of a scientist in a lab writing on a digital stilus with a digital pen.

Scientific microscope with visual representation of DNA helix

Trethera Receives $1.6 Million National Eye Institute Grant for Continued Advancement of TRE-515 Optic Neuritis Program

October 19, 2022

Trethera was awarded a $1.6M National Eye Institute Fast-Track STTR grant to advance the development of TRE‑515 for optic neuritis. The grant supports preclinical IND-enabling studies in collaboration with UCLA, Stanford, and Harvard.

Read More 

Trethera Announces Multiple Sclerosis Treatment Poster Presentation at the American Neurological Association Annual Meeting



October 4, 2022

Trethera will present a poster at the ANA Annual Meeting where UCLA’s Dr. Peter Clark will highlight preclinical data showing that TRE‑515, a dCK inhibitor, selectively reduces autoimmune symptoms in MS mouse models, with implications for optic neuritis treatment.

Read More 

U.S. Patent Office Issues Trethera Composition of Matter Patent Covering TRE-515, Extending Market Exclusivity to Late 2041



September 20, 2022

The USPTO issued a composition of matter patent for the polymorphic form of TRE‑515, extending its U.S. market exclusivity through at least November 2041. This patent covers TRE-515’s unique chemical structure and supports its broad therapeutic use.

Read More 

Trethera and UCLA Publish Data Demonstrating TRE-515 Ability to Control and Improve Multiple Sclerosis Symptoms in Mouse Models



September 7, 2022

Trethera and UCLA published peer-reviewed findings showing that TRE‑515 selectively inhibits autoreactive lymphocytes in mouse models of multiple sclerosis, resulting in improved symptoms without impairing healthy immune function.

Read More 

Trethera Receives U.S. Patent Office Notice of Allowance Covering TRE-515 Structural Claims, Extending Protections to Late 2041



August 17, 2022

Trethera has been issued a USPTO Notice of Allowance for TRE‑515’s structural composition of matter patent, extending its U.S. market exclusivity through November 2041. The patent covers the unique TRE‑515 chemical structure across therapeutic areas.

Read More 